Skip to content

Limb Girdle Muscular Dystrophy (LGMD) Natural History

Longitudinal Assessment and Genetic Understanding of Limb-Girdle Muscular Dystrophy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01783509
Enrollment
13
Registered
2013-02-05
Start date
2011-11-30
Completion date
2017-07-31
Last updated
2022-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)

Keywords

GENETICALLY CONFIRMED limb girdle muscular dystrophy

Brief summary

The purpose of this study is to understand more about limb-girdle muscular dystrophy. Therefore, the investigators would like to track the following information collected once a year from patients with GENETICALLY CONFIRMED LGMD: quality of life questionnaires, muscle strength, motor function, routine examination, assessment of patient (or parent) understanding of LGMD, and serum (blood) for growth factors, cytokines, and biomarkers (all parts of your blood). By tracking this information, we hope to be able to understand more about the diagnosis, progression and natural history of this disorder.

Interventions

None listed

Sponsors

Muscular Dystrophy Association
CollaboratorOTHER
Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* You have a GENETICALLY CONFIRMED diagnosis of Limb Girdle Muscular Dystrophy * You must be at least 6 years of age or older (if under 18 you will need Parental consent) * You must be able to travel to the study site * You must be able to provide a DNA/Gene testing report that confirms a diagnosis of LGMD

Exclusion criteria

* You or your child do not have a diagnosis of LGMD * Your child is under age 6 * You or your child are not able to travel to the study site

Design outcomes

Primary

MeasureTime frame
Comprehensive clinical evaluation of individuals with GENETICALLY CONFIRMED LGMD, according to the study protocol, in order to evaluate disease progressionyearly up to 10 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026